Biosimilar Newsletter Archive

31. 03.28.19 -- Are Biologics Facing A Buy-And-Bill Renaissance?
    3/28/2019
    03/28/19 Biosimilar Development Newsletter
32. 03.21.19 -- Why These Two Biosimilar Policies Raise Questions
    3/21/2019
    03/21/19 Biosimilar Development Newsletter
33. 03.14.19 -- Biosimilar Success: It's Not That Risky To Attain
    3/14/2019
    03/14/19 Biosimilar Development Newsletter
34. 03.07.19 -- How Can FDA Fix The Biosimilar Pathway?
    3/7/2019
    03/07/19 Biosimilar Development Newsletter
35. 03.05.19 -- Integrating Automation And Data Science To Optimize Process Strategies
    3/5/2019
    03/05/19 Biosimilar Development Newsletter
36. 02.28.19 -- Why Medicare's IPI Will Challenge Biosimilars, Payers
    2/28/2019
    02/28/19 Biosimilar Development Newsletter
37. 02.21.19 -- Why This U.S. Biosimilar Initiative Is One To Watch
    2/21/2019
    02/21/19 Biosimilar Development Newsletter
38. 02.14.19 -- Biosimilar Sustainability Requires A Step-Wise Approach
    2/14/2019
    02/14/19 Biosimilar Development Newsletter
39. 02.07.19 -- How Has Biosimilar Real-World Evidence Evolved?
    2/7/2019
    02/07/19 Biosimilar Development Newsletter
40. 02.05.19 -- Biomanufacturing Facility Design: Considerations For Capacity, Flexibility, And Forecasting
    2/5/2019
    02/05/19 Biosimilar Development Newsletter